GSK
GSK plc
$52.97
▼ 1.3%Updated Today 12:11 PM ET
GSK at a glance — five pillars scored 0–100 from real filed financials.
Overall: Favorable · 66/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 39.0% over the last 12 months
Market Cap
$102.51B
P/E
13.77x
Forward P/E (est.)
9.84x
ROE
35.8%
Revenue Growth
4.0%
EPS Growth
86.7%
Profit Margin
17.8%
FCF Yield
3.8%
Debt / Equity
1.08x
ROIC
—
Interest Coverage
—
Current Ratio
—
Dividend Yield
3.5%
Implied Growth (rev. DCF)
—
Rating Score
66/100
GSK plc (GSK) is a large-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $102.51B.
Our model rates GSK Favorable (66/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what GSK's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. GSK trades near $52.97, above its 50-day average ($51.55) and 200-day average ($50.67). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 50 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. GSK's is $1.25 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month GSK found buyers near $50.35 (support) and sellers near $53.84 (resistance); its 52-week range is $35.45–$61.70. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.6× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Where GSK sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 53 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How GSK stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (198 S&P 500 companies), GSK ranks #9 of 198 by our overall rating. It trades at a discount versus the sector on earnings (13.8x P/E vs. 25.5x median) with a higher return on equity (35.8% vs. 14.5%) and slower revenue growth (4.0% vs. 7.6%).
P/E vs sector
13.8x
median 25.5x
ROE vs sector
35.8%
median 14.5%
Growth vs sector
4.0%
median 7.6%
Sector rank
#9
of 198 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 198 S&P 500 names in the sector. Educational, not a recommendation.
The case for GSK:
- High net margins (17.8%) point to pricing power or efficiency.
- Strong return on equity (35.8%) shows capital is put to work well.
- Pays a 3.5% dividend on top of any price gains.
- Our model's overall read is Favorable (66/100).
The case against GSK:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Balance-sheet risk — debt/equity of 1.1x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: GSK plc is a large-cap health care business growing at a mature pace, with solid profitability, and a heavier debt load to watch. It trades at 13.8x earnings, which our model scores Favorable (66/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
GSK — frequently asked questions
Is GSK a good stock to buy?
We don't give buy or sell advice. Our model rates GSK plc Favorable (66/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is GSK's rating on The Stocks School?
GSK plc currently scores 66/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does GSK's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from GSK plc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for GSK calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this GSK analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell GSK. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.